title: Vedolizumab for the treatment of ulcerative colitis.
abstract: A substantial proportion of patients with ulcerative colitis (UC) have failed conventional therapies such as steroids, immunosuppressants or TNF-antibodies, or have experienced side effects. This article reviews the pharmacological properties of vedolizumab (VDZ), its efficacy and side effects in UC. By its relatively specific gut-selective mode of action, VDZ's safety profile appears more favorable than that of anti-TNF therapies. VDZ is more effective than placebo for the induction and maintenance of remission in moderate-to-severe UC in both naïve patients and patients who have failed anti-TNF treatment. However, in some patients, VDZ has a slower onset of action. But, to place VDZ as a first-line therapy, it must go head-to-head with azathioprine and anti-TNF antibodies in future studies.
authors.affiliation: a Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases) , University Hospital Jena , Jena , Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Stallmach
authors.affiliation: a Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases) , University Hospital Jena , Jena , Germany.
authors.forename: Carsten
authors.initials: C
authors.lastname: Schmidt
authors.affiliation: b Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten , Leipzig , Germany.
authors.forename: Niels
authors.initials: N
authors.lastname: Teich
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors* / Q000276:immunology; D058990:Molecular Targeted Therapy; D012074:Remission Induction; D012720:Severity of Illness Index; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D016023:Integrins; C071777:integrin alpha4beta7; C543529:vedolizumab
keywords: Vedolizumab; efficacy; pharmacokinetics; side effects; ulcerative colitis